Akeso saw the highest growth of 1.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.36% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Akeso’s patent filings and grants. Buy the databook here.
Akeso has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 30% filings and 50% grants. The European Patent Office(EPO), Australia(AU), South Korea(KR), and Israel(IL) patent Office are among the top ten patent offices where Akeso is filings its patents. Among the top granted patent authorities, Akeso has 50% of its grants in European Patent Office(EPO) and 50% in Israel(IL).
Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Akeso
Patents related to climate change and health & wellness lead Akeso's portfolio
Akeso has the highest number of patents in climate change followed by, health & wellness and rare diseases. For climate change, nearly 60% of patents were filed and no patents were granted in Q2 2024.
Food related patents lead Akeso portfolio followed by other ingredients, and rectal cancer
Akeso has highest number of patents in food followed by other ingredients, rectal cancer, germ cell tumors, and fallopian tube cancer.
For comprehensive analysis of Akeso's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.